Blaine Davis - Jan 2, 2025 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role
Chief Financial Officer
Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Blaine Davis
Stock symbol
RNAC
Transactions as of
Jan 2, 2025
Transactions value $
$0
Form type
4
Date filed
1/6/2025, 04:20 PM
Previous filing
Jan 4, 2024
Next filing
Jan 7, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Award $0 +22K +27.23% $0.00 103K Jan 2, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNAC Employee Stock Option (right to buy) Award $0 +64.6K $0.00 64.6K Jan 2, 2025 Common Stock 64.6K $16.93 Direct F3
holding RNAC Employee Stock Option (right to buy) 104K Jan 2, 2025 Common Stock 104K $19.66 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.
F2 On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F3 This option vests as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.
F4 This option vested as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter.